Advances in hematopoietic SCT (HSCT) technology and supportive care have led to improvements in long-term survival after HSCT.
1
Long-term survivors aim to recover a normal health and social life. 2, 3 Gonadal dysfunction with the absence of sperm production leading to definitive infertility is a common long-term sequela after HSCT. Fertility and paternity issues are frequent problems that long-term survivors and their respective partner face and it represents a challenge for the transplantation team. Several published studies have reported data on the rate of paternity after allogeneic HSCT, [4] [5] [6] [7] however, these publications did not address patient attitudes and the wish of paternity after HSCT.
Recently, the Late Effects Working Party of the EBMT published a retrospective study on 224 male patients in whom sperm production after allogeneic HSCT was evaluated. 8 This study provided information about potential male fertility after allogeneic HSCT. We report here, from the same cohort of patients, data on paternity before and after HSCT, as well as data regarding wishes for paternity. Participating centers reported for each patient specific information related to the number of fathered children before and after HSCT, the number of adopted children, methods for conception (assisted reproductive techniques versus natural) and availability of cryopreserved sperm collected before HSCT. Additional information on wishes for paternity was requested. Out of 224 patients, 195 (87%) were transplanted for a malignant hematological disease and 155 (69%) were transplanted before the year 2000. TBI (47.5 Gy) was part of the conditioning in 146 (66%) patients, 44 (20%) were conditioned with BU-based regimen and 31 (14%) without TBI or BU. During the follow-up, 142/222 (64%) recipients presented with acute GVHD and 134/220 (61%) with chronic GVHD. In 7 patients data about paternity was missed, we based the present analysis thus on 217 patients. Data on wishes of paternity were provided by 145 patients.
Before HSCT, 53/217 (24%) patients with a median age at HSCT of 36 (range 22-59) years had at least one child (total number of children 84). After HSCT, 29/217 (13%) patients with a median age at HSCT of 21 (2-55) years became father (total number of children 44). The median time interval between HSCT and the birth of the first child was 7.2 (1-21.6) years. Ninety percent of the patients who had a child before HSCT and only 28% of the patients without a child were older than 25 years at HSCT. From 145 patients with available information about wishes for paternity, 31/145 had a child before HSCT and 114 were childless. Seven out of 31 (22%) patients who had a child before HSCT wished to father a child after HSCT, whereas 89/114 (78%) of childless patients had wishes for paternity after HSCT. Hence, patients who had a child before HSCT were significantly older at HSCT (Po0.0001) and had less desire to conceive a child after HSCT (Po0.00001). Having or not a child before HSCT did not influence the number of children fathered after HSCT (P ¼ 0.355). In this study GVHD did not influence the rate of fatherhood; indeed many recipients became fathers through assisted methods using cryopreserved sperm, which could be the explanation for this result. Chronic GVHD showed a borderline negative impact (P ¼ 0.054) with less wish to become a father. Twenty-four percent of the patients had cryopreserved sperm before HSCT, regardless of fatherhood before HSCT (5/32; 16% with children before HSCT; 30/112; 27% without children; P ¼ 0.194). Among the patients who fathered a child after HSCT, 8 were normozoospermic and conceived in a natural way, 3 were oligozoospermic (natural conception 1; cryopreserved sperm 1; unknown 1), 4 were severely oligozoospermic (natural conception 2; unknown 2), 10 had azoospermia (all conceived through an assisted technique) and 4 patients had no available data. Furthermore, four recipients adopted a child; none of them had children before HSCT. These patients were not considered for analysis in the group who fathered a child after HSCT.
Here, we show for the first time data on the wish to become father after HSCT. In this cohort, the wish to father a child after HSCT depends mainly on the paternity status before transplantation and the age at HSCT. Actually, the majority of the patients (76%) did not have children before HSCT and were younger. Irrespective of the high expectancy to father a child (78%) in this population, they did not have a higher rate of pregnancy (15%) compared with those patients who fathered a child before HSCT. Patients with children before HSCT were older, showed lower wish to father a child after HSCT (22%) and had a pregnancy rate of 10% (P ¼ 0.355; Table 1 ). The discrepancy between the wish to father a child and the rate of becoming a father after HSCT can be explained mainly by the degree of infertility after transplantation, independent of the wishes for paternity. Chronic GVHD seems to impact negatively on paternity willingness. Chronic GVHD correlates indeed with increases burden of morbidity in the long-term survivors; certainly patients with chronic illness may be less concerned about fatherhood. A number of physical, psychological and social factors may also influence the decision for paternity, however, these were not analyzed in this study.
This study did not evaluate the reasons or barriers that patients and centers were confronted with for sperm cryopreservation. 9 The low rate of sperm cryopreservation was observed all through the decades (Table 1 ). This datum may show the lack of standardization of sperm banking among different participating countries and centers, and also the deficiency of health-care policies on long-term conservation of cryopreserved seminal fluids. Unsuccessful attempts to collect sperm were not reported. Having a child before HSCT did not significantly influence the rate of cryopreservation.
In conclusion, this study shows that a high proportion of longterm male survivors after allogeneic HSCT have a desire to become fathers, most of whom can satisfy their expectations only if previous sperm cryopreservation has been done. New modalities in the conditioning regimens introduced during the last decade may lead to less gonadal toxicity. However, until definitive fertility data become available, sperm preservation should be offered systematically to all patients as soon as the diagnosis of a hematological disease has been established. 
